Outpatient Parenteral Therapy for Complicated *Staphylococcus aureus* Infections: A Snapshot of Processes and Outcomes in the Real World

Jennifer Townsend, Sara Keller, Martin Tibuaku, Sameer Thakker, Bailey Webster, Maya Siegel, Kevin J. Psoter, Omar Mansour, and Trish M. Perl

1Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland; 2Armstrong Institute of Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, Maryland; 3Department of Medicine, St. Luke’s Hospital, Chesterfield, Missouri; 4Johns Hopkins University Medical School, Baltimore, Maryland; 5Johns Hopkins University School of Nursing, Baltimore, Maryland; 6Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; 7Division of General Pediatrics and Adolescent Health, Johns Hopkins University School of Medicine, Baltimore, Maryland; 8Center for Drug Safety and Effectiveness, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 9Division of Infectious Diseases and Geographic Medicine, UT Southwestern Medical Center, Dallas, Texas

**Background.** In the United States, patients discharged on outpatient parenteral antimicrobial therapy (OPAT) are often treated by home health companies (HHCs) or skilled nursing facilities (SNFs). Little is known about differences in processes and outcomes between these sites of care.

**Methods.** We performed a retrospective study of 107 patients with complicated *Staphylococcus aureus* infections discharged on OPAT from 2 academic medical centers. Clinical characteristics, site of posthospital care, process measures (lab test monitoring, clinic follow-up), adverse events (adverse drug events, *Clostridium difficile* infection, line events), and clinical outcomes at 90 days (cure, relapse, hospital readmission) were collected. Comparisons between HHCs and SNFs were conducted.

**Results.** Overall, 33% of patients experienced an adverse event during OPAT, and 64% were readmitted at 90 days. Labs were received for 44% of patients in SNFs and 56% of patients in HHCs. At 90 days after discharge, a higher proportion of patients discharged to an SNF were lost to follow-up (17% vs 3%; *P* = .03) and had line-related adverse events (18% vs 2%; *P* < .01). Patients discharged to both sites of care experienced similar clinical outcomes, with favorable outcomes occurring in 61% of SNF patients and 70% of HHC patients at 90 days. There were no differences in rates of relapse, readmission, or mortality.

**Conclusions.** Patients discharged to SNFs may be at higher risk for line events than patients discharged to HHCs. Efforts should be made to strengthen basic OPAT processes, such as lab monitoring and clinic follow-up, at both sites of care.

**Keywords.** hospital readmissions; infectious disease; OPAT, *Staphylococcus aureus*.

Outpatient parenteral antimicrobial therapy (OPAT) is the standard of care for patients requiring long-term parenteral antimicrobials and is utilized to facilitate early hospital discharge for patients with infections [1]. These programs are patient-centric, cost-effective [2–4], and safe [5] alternatives to inpatient hospitalization for intravenous (IV) antimicrobial treatment. In the United States, OPAT is administered in a variety of settings including via home health companies (HHCs) and skilled nursing facilities (SNFs).

Despite broad acceptance of OPAT programs in the United States, little is known about patient- and program-level outcomes. Reports of processes and outcomes of OPAT care have been limited to single-center studies [6–9], with few studies explicitly comparing outcomes in SNFs vs HHCs. For example, an analysis of OPAT processes from the University of Pennsylvania found that HHC patients were more likely than SNF patients to have labs seen by an infectious diseases (ID) professional within 1 week of discharge (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.51–3.65) and to attend follow-up appointments (OR, 2.57; 95% CI, 1.56–3.89). In terms of outcomes, HHC patients were less likely to have an adverse drug event (OR, 0.52; 95% CI, 0.29–0.91) and a relapse or clinical failure compared with SNF patients (OR, 0.49, 95% CI, 0.27–0.89) [6].

Bhavan et al. described the outcomes of the OPAT program at a safety net hospital, Parkland Hospital in Dallas, Texas, comparing the results of uninsured patients discharged to home self-administer antimicrobials (s-OPAT) with the more traditional cohort of patients with insurance discharged to SNFs and HHCs (H-OPAT). The 30-day readmission rate in the H-OPAT group was 21%, compared with 16.7% in the S-OPAT group. The authors only provided a combined outcome and did not differentiate between those linked to SNFs vs HHCs. For patients and insurers to make more informed decisions about posthospital...
OPAT care, more evidence is needed that compares outcomes for these varied sites of care.

We addressed this data gap among a cohort of patients with complicated *Staphylococcus aureus* (SA) infections from 2 academic medical centers in our system. Given the virulence of SA and the toxicity of first-line antimicrobials (oxacillin [10] and vancomycin [11]), patients receiving these agents require close follow-up to prevent both adverse drug events and relapsing infection [12, 13]. We presumed that by following the longitudinal OPAT course of this group, we could observe our OPAT program “at its best.” The objectives of our study were to (1) characterize current OPAT processes and outcomes for complicated SA cases and (2) compare OPAT processes and outcomes among patients receiving antimicrobials in HHCs vs SNFs.

**METHODS**

**Hospitals and Setting**

Johns Hopkins Bayview Medical Center (BMC), a 440-bed academic tertiary care center, and the Johns Hopkins Hospital (JHH), a 1194-bed academic quaternary care center, serve Baltimore, Maryland, and the surrounding area. Both acute care hospitals have access to inpatient and outpatient infectious diseases consult services.

**OPAT Program Description**

Before the study period (1/2013–12/2014), there was no systematic OPAT data collection. Beginning in 2013, hospital case managers referred some, but not all, adult OPAT patients to the outpatient ID clinic at the time of discharge. ID consultation was not mandatory before discharge, and all OPAT orders were placed by the discharging provider, who had no role in following the patient in the outpatient setting. In general, these patients were seen in the ID clinic for routine visits between 1 week and 3 weeks after discharge. A small percentage of skilled nursing facilities (~5%) in our area contract with ID physicians to manage patients on long-term antibiotics, but our ID division was not routinely notified about the findings of these rounds. Outpatient antibiotics were administered by a variety of HHCs and SNFs depending on patient insurance contracts and medical needs. Between visits at BMC, a nurse practitioner called SNFs and HHCs for missing results. At JHH, medical office coordinators placed calls at provider request. The BMC ID nurse practitioner was the only resource dedicated to the OPAT program.

**Patient Selection and Data Collection**

We identified complicated SA cases discharged on OPAT from our health system. First, between January 2013 and December 2014, patients who grew SA from a sterile source during an inpatient admission were identified from microbiology laboratory data. To generate a feasible number of records for manual data extraction, every second patient encounter was selected for manual chart review. Based on medical record review, patients with a complicated infection during their hospital stay were included. Complicated infections were defined as infections of bone and joint (osteomyelitis, septic arthritis, prosthetic joint infections, vertebral osteomyelitis, or discitis), central nervous system (cranioplasty site infections, ventricular shunt infections, meningitis, or spinal epidural abscess), and endovascular sources (catheter-associated bloodstream infections, endocarditis, vascular graft infections, or septic thrombophlebitis) requiring more than 2 weeks of IV therapy. Skin and soft tissue infections, intra-abdominal infections, and pneumonia were excluded. Patients who elected to be followed by physicians outside of our health system were excluded as records were not routinely available for review.

Clinical characteristics were recorded on a standardized case review form, including demographic information, clinical outcomes, adverse events related to medications or vascular access, and readmissions at 30 and 90 days after the initial index discharge. Clinical data were extracted via manual review of the electronic medical record (EMR) and from the institutional data warehouse (PREMIER QualityAdvisor Database, Premier Inc., Charlotte, NC) using patient-level queries of billing data and administrative codes (International Classification of Diseases, 9th Revision) (Supplementary Table 1). To validate the data abstraction, 12 charts (11%) were randomly selected and reviewed by an external reviewer. The interrater reliability was 0.97 (κ, 0.97; 95% confidence interval [CI], 0.93–1.0).

### Outcome Definitions

The primary outcome was treatment outcome at 90 days. A favorable outcome (“cure”) was defined as a patient who was clinically improved and without evidence of infection, without antimicrobials or on suppressive oral antimicrobials in the setting of retained hardware or a nonremovable source. An unfavorable outcome (“treatment failure”) was defined as a patient who did not meet the above criteria for cure, was lost to follow-up, had a relapse, or was placed in hospice. Relapse was defined as any of the following after a period of clinical improvement and hospital discharge: isolation of SA with the same susceptibility pattern as the index episode from the blood or other sterile clinical specimen, recurrence of previous symptoms, radiographic evidence of worsening at the site of the previous source requiring additional antimicrobial therapy, change in antimicrobial therapy due to progression of infection (not due to adverse drug event), additional surgical or radiologic procedure for control of infection, or other source control intervention. If a patient relapsed any time before 90 days, treatment was modified, and they improved again before the end of 90 days, he or she was still considered a relapse for the purposes of our analysis.

Secondary outcomes included adverse events associated with IV catheters or medications, 30- and 90-day readmission, and death during the follow-up period.

Encounters with an ID provider were documented as ID follow-up. Patients were considered lost to follow-up if they...
did not have any encounters with a provider addressing their infection or antibiotic course at or after the specified follow-up time point.

Adverse events (AEs) included adverse drug events (ADEs) and were defined as unfavorable and unintended signs, laboratory findings, or symptoms temporally associated with and thought by the treatment team to be a consequence of an antimicrobial or device. This included *Clostridium difficile* colitis with onset after discharge. Catheter complications included (1) catheter infection, defined as a laboratory-confirmed bloodstream infection in a patient with a central catheter, or an IV catheter site infection surrounding the catheter insertion site [14], or clinical sepsis that resolved after line removal; or (2) noninfectious line events such as external leakage, extravasation, or catheter-associated venous thromboembolism, or if the line became dislodged or accidentally removed, necessitating line replacement [15]. AEs were noted by reviewing clinical documentation after hospital discharge.

In the case of ADEs, if patients received multiple medications throughout their course, the culprit medication was determined based on the timing of administration (medications given after the reaction were ignored) and the frequency of adverse events listed in drug monographs Wolters Kluwer Clinical Drug Information, Inc. (Lexi-Drugs). Wolters Kluwer Clinical Drug Information, Inc.; April 15, 2013.

**Comorbidities and Process Definitions**

Immunocompromised patients were defined as those having the following conditions during hospital admission: uncontrolled diabetes with a hemoglobin A1c >8, use of prednisone (14 days of 10 mg/d or greater), or immunosuppressants or chemotherapy within the preceding 6 months (ie, tumor necrosis factor inhibitors, calcineurin inhibitors), AIDS with a CD4 <250, presence of solid organ or bone marrow transplant, or neutropenia (absolute neutrophil count < 1000 cells/µL for ≥7 days).

The 3M All-Patient Refined Diagnosis-Related Groups (APR-DRG) severity subclass is a calculated measure of the extent of physiologic decompensation or organ system loss of function and is used to measure the complexity of a hospital's patient case mix [16]. The metric considers the patient's multiple comorbidities and any complications of the index hospitalization and is useful for predicting readmissions [17]. A severity score (1 = minor severity, 2 = moderate, 3 = severe, 4 = extreme) was assigned for each patient at the time of discharge using a proprietary algorithm and was extracted from the institutional Electronic Data Warehouse (EDW).

Source control was defined as a procedure or intervention to drain, debulk, or remove the source of infection. Examples included removal of infected catheters, incision and drainage of abscesses, and revision of a prosthetic joint. Patients were not required to have full hardware removal to meet criteria for source control if the infected site was washed or drained in an attempt to remove as much infection as possible.

We defined patient noncompliance as clinician documentation of patient refusal of recommended source control procedure during hospital admission, refusal of antimicrobials during admission or follow-up, not presenting to any clinic visits 30 days after discharge, refusing lab draws or home nursing services, or leaving a skilled nursing facility against medical advice.

Laboratory tests were obtained weekly, as is recommended by national guidelines [18]. For instance, if a patient was on parenteral therapy for 17 days, we defined this individual as having 2 patient-weeks, or 2 lab opportunities. If the clinic received any requested labs (including incomplete sets of labs) during an OPAT patient-week, this was counted as lab completion for that patient-week.

**Statistical Analysis**

Demographic and clinical features of OPAT patients with complicated SA infections discharged to SNFs were compared with those discharged to HHCs using Student *t* tests with unequal variances and chi-square or Fisher exact tests for continuous and categorical variables, respectively. OPAT processes and outcomes were then compared between groups in a similar manner. Finally, we examined individual-level characteristics and their association with unfavorable outcomes at 90 days using logistic regression. Gender and APRDRG were the only 2 variables that were statistically significantly associated with 90-day outcomes in these exploratory analyses; a multivariable logistic regression was then used to evaluate the direction and magnitude of these associations following adjustment for discharge site, age, mental illness, and type of infection (methicillin-resistant SA [MRSA] or methicillin-sensitive SA [MSSA]). The results of these models are presented as odds ratios with corresponding 95% confidence intervals. A *P* value <.05 was considered statistically significant. All analyses were performed using STATA, version 14.1 (College Station, TX, USA).

**RESULTS**

**Patient Selection**

Overall, we identified 553 patients with cultures growing SA from sterile sites between January 2013 and December 2014. Of the 281 medical records reviewed, 174 patients were excluded. Those excluded had uncomplicated infections (n = 55), were not discharged on IV antimicrobials (n = 89), SA was not the primary pathogen (n = 22), or there were no outcomes data (n = 1). Among the 107 eligible patients comprising the study population, 62% (n = 66) were discharged to an HHC and 38% (n = 41) were discharged to an SNF.

**Patient Demographics and Clinical Characteristics**

Demographic and clinical characteristics were similar in both SNF and HHC groups. A majority of patients were male (57%), and Medicare was the most common insurance type in
Table 1. Clinical Features of Patients With Complicated Staphylococcal Infections Discharged on OPAT Between 1/2013 and 12/2014, Comparing Patients Discharged to Skilled Nursing Facilities vs Home Health

|                                      | Overall | Skilled Nursing Facility | Home Health | P Value |
|--------------------------------------|---------|--------------------------|-------------|---------|
|                                      | No.     | %                        | No.         | %       | No.     | %       |         |
|                                      | (n = 107)|                          | (n = 41)    | 38.3    | (n = 66) | 61.6    |         |
| Social and demographic features      |         |                          |             |         |         |         |         |
| Male gender                          | 61      | 57.0                     | 21          | 52.5    | 40       | 60.6    | .54      |
| Mean age, y                          | 54.1    | 173                      | 58.4        | 16.3    | 51.3     | 176     | .04      |
| Race                                 |         |                          |             |         |         |         |         |
| White                                | 71      | 66.4                     | 31          | 75.0    | 40       | 60.6    |         |
| Black                                | 30      | 28.0                     | 8           | 20.0    | 22       | 33.3    |         |
| Unavailable                          | 5       | 4.7                      | 2           | 5.0     | 3        | 4.5     |         |
| Asian                                | 1       | 0.9                      | 0           | 0.0     | 1        | 1.5     | .38      |
| Insurance                            |         |                          |             |         |         |         |         |
| Medicare                             | 48      | 44.9                     | 23          | 55.0    | 25       | 37.9    | .14      |
| Commercial insurance                 | 29      | 27.1                     | 7           | 175     | 22       | 33.3    |         |
| Medicaid                             | 25      | 23.4                     | 8           | 20.0    | 17       | 25.8    |         |
| Self-pay                             | 5       | 4.7                      | 3           | 7.5     | 2        | 3.0     |         |
| Social support                       |         |                          |             |         |         |         |         |
| Lives with others                    | 74      | 69.2                     | 26          | 62.5    | 48       | 72.7    |         |
| Lives alone, has support             | 20      | 18.7                     | 6           | 15.0    | 14       | 21.2    |         |
| Unknown                              | 9       | 8.4                      | 5           | 12.5    | 4        | 6.1     |         |
| Lives alone, no support              | 4       | 3.7                      | 4           | 10.0    | 0        | 0.0     | .04      |
| History of intravenous drug abuse    | 7       | 6.5                      | 4           | 10.0    | 3        | 4.5     | .42      |
| Hospitalized in past 3 mo            | 57      | 53.3                     | 26          | 65.0    | 30       | 45.5    | .08      |
| Comorbid conditions at hospital discharge |         |                          |             |         |         |         |         |
| APRDRG severity subclass             |         |                          |             |         |         |         |         |
| 1                                    | 1       | 0.9                      | 0           | 0.0     | 1        | 1.5     | .30      |
| 2                                    | 25      | 23.4                     | 7           | 175     | 18       | 273     |         |
| 3                                    | 38      | 35.5                     | 13          | 32.5    | 25       | 379     |         |
| 4                                    | 43      | 40.2                     | 21          | 50.0    | 22       | 33.3    |         |
| Wound care needs                     | 39      | 36.4                     | 12          | 30.0    | 26       | 39.4    | .44      |
| Severe neurologic compromise         | 37      | 34.6                     | 18          | 45.0    | 18       | 273     | .10      |
| Immunocompromise                     | 31      | 29.0                     | 10          | 25.0    | 21       | 31.8    | .60      |
| Mental illness or psychiatric disturbance | 25      | 23.4                     | 13          | 32.5    | 12       | 18.2    | .15      |
| Major fracture or amputation         | 7       | 6.5                      | 5           | 12.5    | 2        | 3.0     | .10      |
| Characteristics of infection         |         |                          |             |         |         |         |         |
| Site of infection                    |         |                          |             |         |         |         |         |
| Musculoskeletal                      | 58      | 54.2                     | 26          | 63.4    | 32       | 48.5    | .16      |
| Endovascular                         | 40      | 37.4                     | 13          | 31.7    | 27       | 40.9    | .41      |
| Central nervous system               | 9       | 8.4                      | 2           | 4.9     | 7        | 10.6    | .47      |
| Bacteremia present                   | 69      | 64.5                     | 30          | 73.2    | 39       | 59.1    | .24      |
| Prosthetic material infected         | 51      | 47.7                     | 22          | 53.7    | 29       | 43.9    | .51      |
| Microorganism                        |         |                          |             |         |         |         |         |
| MSSA                                  | 58      | 54.2                     | 19          | 46.34   | 39       | 59.1    | .23      |
| MRSA                                 | 52      | 48.6                     | 22          | 55.0    | 30       | 45.5    | .45      |
| Polymicrobial                         | 29      | 27.6                     | 11          | 27.5    | 18       | 28.1    | 1.00     |
| Antibiotic at discharge              |         |                          |             |         |         |         |         |
| Vancomycin                           | 49      | 45.8                     | 21          | 52.5    | 28       | 42.4    | .42      |
| Oxacillin                            | 42      | 39.3                     | 16          | 40.0    | 26       | 39.4    | 1.00     |
| Cefazolin                            | 13      | 12.1                     | 4           | 9.8     | 9        | 13.6    | .53      |
| Daptomycin                           | 3       | 2.8                      | 0           | 0.0     | 3        | 4.5     | .29      |
| Ceftriaxone                          | 2       | 1.9                      | 0           | 0.0     | 2        | 3.0     | .53      |
| Intravenous access at discharge      |         |                          |             |         |         |         |         |
| Peripherally inserted central catheter| 82      | 76.6                     | 30          | 75.0    | 52       | 78.8    |         |
| Tunnelled central line               | 22      | 20.6                     | 10          | 24.4    | 12       | 18.2    | .69      |
| Mediport                             | 2       | 1.9                      | 1           | 2.5     | 1        | 1.5     |         |
| Fistula                              | 1       | 0.9                      | 0           | 0.0     | 1        | 1.5     |         |

Abbreviations: APRDRG, All-Patient Refined Diagnosis-Related Group; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; OPAT, outpatient parenteral antibiotic therapy.
both groups (45%). Patients treated by HHCs were younger (51 years vs 58 years; \( P = .04 \)) (Table 1). A majority of patients had been hospitalized within 3 months before the index admission (53%). Vancomycin, followed by oxacillin, was the most common antimicrobial used after discharge (46% and 39%, respectively). Most of the patients who required source control underwent appropriate procedures (n = 87, 92%) during hospital admission.

**OPAT Processes**

The OPAT processes at our institutions were similar in both groups (Table 2). Most patients (87%) were seen by an ID consultant before discharge, but only 55% of people were seen in the ID clinic after discharge. At least 1 laboratory study was obtained in 51% of OPAT patients. When considering all weekly labs, the OPAT practitioners received 109 partial or complete sets of labs for 485 weeks of OPAT (22%).

Many of the OPAT processes of care were similar between patients in SNFs or with HHCCs (Table 2). The ID clinic received results from 44% of SNF patients and 56% of HHC patients (\( P = .25 \)). At the 90-day follow-up, the proportion of patients retained in care within our health system (any provider) was significantly higher among patients discharged to HHCs than for SNFs (97% vs 83%, respectively; \( P = .05 \)). A significantly greater proportion of line-related AEs occurred in the SNF group vs the HHC group (18% vs 2%; \( P < .01 \)).

**OPAT Outcomes**

In total, 35 patients (33%) suffered 37 AEs, and 17 were readmitted (Table 3). A majority of events were ADEs (n = 26, 70%), line complications (n = 8, 22%), and several were due to *Clostridium difficile* (n = 3, 8%). Sixteen of the 26 ADEs (62%) resulted in a change of therapy or premature termination of treatment. ADEs occurred in 20% (n = 10/49) of vancomycin courses, 24% of oxacillin (n = 10/42), and 15% of cefazolin (n = 2/13).

At the time of completion of IV antimicrobials, 86% of patients had a favorable outcome. This decreased to 71% at 90 days after discharge due to a relapse rate of 22%. All-cause 30-day and 90-day readmission rates were high (34% and 64%, respectively). In our sample, 53% of 90-day readmissions were related to the OPAT-related complications.

Patients discharged to both sites of care experienced similar clinical outcomes, with favorable outcomes occurring in 61% of SNF patients and 70% of HHC patients at 90 days. There were no differences in rates of relapse, readmission, or mortality.

**Variables Associated With Unfavorable Outcomes at 90 Days**

To determine factors associated with poor outcomes, a multivariable logistic regression adjusted for sex, mental illness, APRDRG severity subclass, MRSA, presence of bacteremia, and site of care determined that males had better outcomes at 90 days (OR, 0.23; 95% CI, 0.07–0.73) and those with higher APR-DRG severity (4) had a 5-fold higher risk of an unfavorable outcome (OR, 5.36; 95% CI, 1.27–22.74) (Table 3). The magnitude and precision of these estimates were similar to univariate associations (results not presented).

**DISCUSSION**

OPAT is a critical component of care as patients transition from hospitals; however, the impact has been poorly studied. In this study, we identified a number of deficiencies in OPAT care processes that present significant threats to patient safety. A third of patients treated at both SNFs and HCCs experienced (37% in SNFs and 35% with HHCs) AEs. Neither SNFs nor HHCs reported weekly laboratory data in a reliable and consistent manner. Half of patients did not have follow-up laboratory

| Table 2. OPAT Process Measures for Patients With Complicated Staphylococcal Infections Discharged on OPAT Between 1/2013 and 12/2014, Comparing Patients Discharged to Skilled Nursing Facilities vs Home Health |
|---------------------------------|-----------------|
| | Overall | Skilled Nursing Facility | Home Health |
| Process measures | No. (n = 107) | % | No. (n = 41) | % | No. (n = 66) | % | P-Value |
| **Hospital management** | | | | | |
| Source control indicated | 95 | 88.8 | 35 | 87.5 | 59 | 89.4 | .76 |
| Source control done (if indicated) | 87 | 81.3 | 34 | 82.9 | 53 | 78.8 | .78 |
| Prosthetic material removed (if present) | 32 | 29.9 | 16 | 39.0 | 16 | 24.2 | .16 |
| ID consult before discharge | 93 | 86.9 | 39 | 95.1 | 54 | 81.8 | .07 |
| ID follow-up arranged | 67 | 62.6 | 27 | 65.9 | 40 | 60.6 | .81 |
| **Postdischarge management** | | | | | |
| Duration of OPAT (average, range) | 31.75 (6–130) | | 31.80 (9–130) | | 31.71 (6–72) | | .19 |
| Seen in ID clinic in follow up while on IV therapy | 59 | 55.0 | 26 | 63.4 | 33 | 50.0 | .23 |
| Labs received by ID | 55 | 51.4 | 18 | 43.9 | 37 | 56.1 | .25 |
| No. of ID visits while on IV therapy, median (IQR) | 2 | 1.0 | 1 | 1 (1–2) | 2 | 1 (1–2) | .07 |
| Patient noncompliance | 13 | 12.1 | 5 | 12.2 | 8 | 12.1 | 1.00 |

Abbreviations: ID, infectious diseases; IQR, interquartile range; IV, intravenous; OPAT, outpatient parenteral antibiotic therapy.
testing in accordance with national guidelines. This is comparable to what other programs have found. One previous study of OPAT processes found that only 37% of laboratory tests were reviewed by an infectious diseases specialist 1 week after hospital discharge [6]. In that study, using a structured team to pursue missing laboratory data increased compliance to 94%. In the era of electronic medical records, phone calls and facsimiles of results may soon be obsolete. However, the transition to

| Table 3. OPAT Outcomes and Predictors of Unfavorable Outcomes at 90 Days for OPAT Patients |
|-------------------------------------|-------------------------------------|
| **Variable**                       | **Overall**                         | **Skilled Nursing Facility** | **Home Health** |
|                                    | **No.**                             | **%**                      | **PValue**      | **No.**                             | **%**                      | **PValue**      |
| OPAT-related adverse events (90 d postdischarge) | 37 | 34.6 | .99 | 15 | 36.8 | 23 | 34.8 | .70 |
| Total patients with adverse events | 35 | 32.7 | .84 | 12 | 29.3 | 23 | 34.8 | .58 |
| Readmission for adverse event      | 17 | 15.9 | .91 | 5 | 12.2 | 12 | 18.2 | .58 |
| Type of adverse event              |                                            |                            |                |
| Adverse drug events                | 26 | 24.3 | .99 | 7 | 17.1 | 19 | 28.8 | .25 |
| Therapy modified or discontinued for ADE | 16 | 15.0 | .46 | 7 | 17.1 | 9 | 13.6 | .84 |
| Line related                       | 8  | 7.5  | .99 | 7 | 17.1 | 1 | 1.5  | .01 |
| Line infection                     | 8  | 7.5  | .99 | 6 | 14.6 | 2 | 3.0  | .05 |
| Noninfectious line complication    | 1  | 0.9  | .99 | 1 | 2.4  | 0 | 0.0  | .99 |
| *Clostridium difficile* infection  | 3  | 2.8  | .99 | 1 | 2.4  | 2 | 3.0  | .80 |
| Treatment outcomes                 |                                            |                            |                |
| At end of OPAT therapy             |                                            |                            |                |
| Favorable                          | 86 | 80.4 | .99 | 31 | 75.6 | 55 | 83.3 | .47 |
| Cure                               | 68 | 63.6 | .99 | 26 | 63.4 | 42 | 63.6 | .99 |
| Suppression                        | 18 | 16.8 | .99 | 5 | 12.2 | 13 | 19.7 | .46 |
| Unfavorable                        | 14 | 13.1 | .99 | 5 | 12.2 | 9 | 13.6 | .99 |
| At 90 d postdischarge              |                                            |                            |                |
| Favorable                          | 71 | 66.4 | .99 | 25 | 61.0 | 46 | 69.7 | .47 |
| Cure                               | 56 | 52.3 | .99 | 21 | 51.2 | 35 | 53.0 | .99 |
| Suppression                        | 15 | 14.0 | .99 | 4 | 9.8  | 11 | 16.7 | .47 |
| Unfavorable                        | 20 | 18.7 | .99 | 9 | 22.0 | 11 | 16.7 | .67 |
| Lost to follow-up                  | 9  | 8.4  | .99 | 7 | 17.1 | 2 | 3.0  | .03 |
| Relapse                            | 22 | 20.6 | .99 | 6 | 14.6 | 15 | 22.7 | .44 |
| Death                              | 6  | 5.6  | .99 | 2 | 4.9  | 4 | 6.1  | .99 |
| Readmission rates                  |                                            |                            |                |
| 30-d readmissions                  | 34 | 31.8 | .82 | 12 | 29.3 | 22 | 33.3 | .82 |
| 90-d readmissions                  | 64 | 59.8 | .22 | 21 | 51.2 | 43 | 65.2 | .22 |
| OPAT-related 90-d readmissions     | 34 | 31.8 | .99 | 13 | 31.7 | 21 | 31.8 | .99 |
| Worsening or relapsing infection   | 17 | 15.9 | .99 | 7 | 17.1 | 10 | 15.2 | .99 |
| Adverse drug event                 | 8  | 7.5  | .99 | 1 | 2.4  | 7 | 10.6 | .15 |
| Line complication                  | 6  | 5.6  | .20 | 4 | 9.8  | 2 | 3.0  | .20 |
| Sequelae of original infection     | 2  | 1.9  | .99 | 1 | 2.4  | 1 | 1.5  | .99 |
| Planned surgery                    | 1  | 0.9  | .99 | 0 | 0.0  | 1 | 1.5  | .99 |
| OPAT-unrelated readmissions        | 30 | 28.0 | .18 | 8  | 19.5 | 22 | 33.3 | .18 |

Multivariable model of predictors of unfavorable outcome at 90 days. Model is adjusted for the variables listed.

| Variable                                      | Adjusted Odds Ratios | 95% CI         | PValue |
|-----------------------------------------------|-----------------------|----------------|--------|
| Male gender                                   | 0.23                  | (0.07–0.73)    | .013   |
| Age                                           | 1.00                  | (0.97–1.03)    | .955   |
| Mental illness                                | 2.22                  | (0.71–6.96)    | .173   |
| APRDRG severity subclass (compared with 2)    |                       |                |        |
| 3                                             | 1.28                  | (0.27–6.10)    | .759   |
| 4                                             | 5.36                  | (1.27–22.34)   | .023   |
| MSRA vs MSSA                                   | 1.22                  | (0.43–3.47)    | .708   |
| Treating facility (SNF vs HHC)                 | 0.66                  | (0.22–1.98)    | .459   |

Abbreviations: ADE, adverse drug event; APRDRG, All-Patient Refined Diagnosis-Related Group; CI, confidence interval; HHC, home health company; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*; OPAT, outpatient parenteral antibiotic therapy; SNF, skilled nursing facility.
electronic data transfer has been hampered by the cost and burdens of electronic data-sharing agreements. These barriers have prevented the implementation of automatic lab transmission to date and negatively impact patient safety. In a large academic medical center report of OPAT outcomes, the lack of availability of recommended laboratory test results was associated with increased readmissions (adjusted OR, 2.53; 95% CI, 1.36–4.73), though causality cannot be confirmed [9].

Second, patients treated at both sites of care experienced high rates of OPAT-related AEs (37% in SNFs and 35% with HHCs). The proportion of patients experiencing a therapy modification for an ADE (15%) is higher than what was reported in the OPAT Outcomes Registry (4.6% of courses stopped early for ADE) [2]. The high ADE rate in this study may be related to inconsistent laboratory testing and follow-up, leading to delayed recognition of drug toxicity, or simply due to a broader definition of ADE than was used in the registry. Commonly used antimicrobials for SA infections (vancomycin for MRSA and oxacillin for MSSA) are associated with significant side effects in the OPAT population [11, 19–23]. The case for OPAT monitoring as a patient safety imperative should be articulated to policy-makers and hospital administrators alike, emphasizing that investments in these processes may reduce overall costs to the health care system via decreased complications and readmissions [6, 9, 24].

Third, the high readmission rates at both time points studied, 30 and 90 days after discharge, further underscore the challenges with treating SA infections. In this era of value-based care, hospitals have strong incentives to reduce readmissions to avoid penalties from payors [25]. In a well-established OPAT program such as the one at Parkland Hospital in Dallas, Texas, which has a strong multidisciplinary tracking system in place, the 30-day readmission and relapse rates for SA infections (including uncomplicated cases) were much lower than in our cohort (20% and 2%, respectively) [13]. Data from previous studies have demonstrated that intentional investments into OPAT staffing and infrastructure can result in substantial improvements in patient outcomes [6, 26–28].

Whether OPAT is provided in an SNF or by HCC, our results demonstrate that care processes need to be strengthened to improve patient safety and adhere to standards of care put forth by national guidelines [18]. In neither setting were laboratory results transmitted to our ID providers or clinic per national recommendations. Furthermore, our findings suggested that patients managed in SNFs were at increased risk of AEs. They were much more likely to have line-related events. As neither SNFs nor HHCs are currently required to report infection rates to regulators or the National Health Surveillance Network, they cannot be compared, and care providers may be unaware of the risks. This finding also aligns with national surveillance reports of high rates of line-associated bloodstream infections in long-term acute care facilities [29]. Challenges of infection control and prevention in long-term care facilities are long-standing and well known [30–32]. Second, patients in SNFs were lost to follow-up more frequently, making it difficult for our program to track and report their outcomes. In reality, the rates of adverse events or unfavorable outcomes may have been even higher than measured in our sample. We investigated whether this poor clinic follow-up was due to patient insurance network restrictions. In a review of 3 months of recent data, we found that 7 of 85 patients (8.2%) had insurance that was not accepted by our ID clinic. If all these patients had been scheduled and kept their appointments, this would have put the follow-up rate at 63%, which is still well below recommended benchmarks.

To overcome the barriers in result transmission and clinical communication, our program is planning to pilot a telemedicine approach with 2 local nursing facilities. The planned workflow is to engage a nursing home provider in a virtual rounding process in which the results and clinical course of OPAT patients are presented and discussed telephonically. The hope is that this process will decrease the amount of time our program staff spend obtaining results and clinical information from these facilities, and potentially avoid transporting well patients back and forth to clinic when no changes to management are necessary.

Our study has several limitations. First, the relatively small sample size precluded a more rigorous analysis of risk factors or predictors of poor outcomes between OPAT settings. This further limited our ability to delve into other factors that contribute to favorable outcomes after discharge to either an SNF or HHC. Although our study population was drawn from 2 participating institutions, it is possible that there are differences in the composition of the sample and the actual population. Second, although our sample was drawn from patients at 2 hospitals, the programs were in the same city and were highly intertwined in terms of processes and resources; therefore, our findings may not be generalizable to other OPAT programs or institutions. Third, the higher observed rate of ADEs among HHC patients may partially be explained by differentially higher rates of lab availability in HHCs compared with SNFs. The higher rate of lab collection and transmission to ID providers may have contributed to ADEs being detected more frequently. Also, a greater proportion of patients in the SNF population were lost to follow-up, ADEs may have occurred at the same rate as HHCs, but patients never returned to clinic to report them.

A further limitation of our study is that our data search was limited to our health system EMRs. We cannot determine from our data if the defect in laboratory test performance is at the level of the SNF or HHC performing the labs, or at the level of result transmission to our care team. Universally, patients at SNFs are seen by in-house providers (occasionally ID physicians) who review results and often modify treatment courses or prescribe new antibiotics. Treatment changes usually come to the attention of the hospital ID team if patients return to clinic or are readmitted to the hospital. Our OPAT team is undertaking efforts to establish clear communication expectations, protocols, and
telemedicine strategies between SNFs and our ID department so that we may be notified earlier of potential adverse events.

Despite clear guidelines for best practices in OPAT, rates of adherence to these practices were low in our population of complicated staphylococcal infections. High AE rates, readmission rates, and relapse rates occurred in our patient sample irrespective of the site of OPAT administration. Site-specific strategies for empowering OPAT programs to adhere to guidelines would likely improve outcomes. Further studies with a larger patient population such as a revitalized national registry are sorely needed to gather outcomes data and drive policies to support best practice and safer care for this population.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
The authors would like to acknowledge Karen Daniels, NP, for her care of these patients. We thank Ann Hanlon for help procuring microbiology data.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Williams DN, Baker CA, Kind AC, Sannes MR. The history and evolution of outpatient parenteral antibiotic therapy (OPAT). Int J Antimicrob Agents 2015; 46:307–12.
2. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis 2010; 51(Suppl 2):S198–208.
3. Ruh CA, Parameswaran GI, Wojciechowski AL, Mergenhagen KA. Outcomes and pharmacoeconomic analysis of a home intravenous antibiotic infusion program in veterans. Clin Ther 2015; 37:2527–35.
4. Psaltikidis EM, Silva END, Bustorff-Silva JM, et al. Economic evaluation of outpatient parenteral antimicrobial therapy: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2017; 17:355–75.
5. Mitchell ED, Czoski Murray C, Meads D, et al. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ Open 2017; 7:e015360.
6. Keller SC, Guffieletti D, Bilker W, et al. The impact of an infectious diseases transition service on the care of outpatients on parenteral antimicrobial therapy. J Pharm Technol 2013; 29:205–14.
7. Bhavan KP, Brown LS, Haley RW. Self-administered outpatient antimicrobial infusion by uninsured patients discharged from a safety-net hospital: a propensity-score-balanced retrospective cohort study. PLoS Med 2015; 12:e1001922.
8. Means LS, Bledsade S, Sikkia M, Gross AE. Predictors of hospital readmission in patients receiving outpatient parenteral antimicrobial therapy. Pharmacotherapy 2016; 36:934–9.
9. Hucht D, Ginsberg JP, Gordon SM, et al. Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. J Antimicrob Chemother 2014; 69:228–33.
10. Lee B, Tam I, Weigel B 4th, et al. Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches. J Antimicrob Chemother 2015; 70:2389–96.
11. Shrestha NK, Mason P, Gordon SM, et al. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. J Antimicrob Chemother 2014; 69:407–15.
12. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066–72.
13. Townsend J, Fellerie J, Peterson G, et al. Quality improvement of Staphylococcus aureus bacteremia management and predictors of relapse-free survival. Am J Med 2016; 129:195–203.
14. Embry FC, Chimnes I (2008). APIC - HICPAC Surveillance Definitions for Home Health Care and Home Hospice Infections (HICPAC): 13. Available at: http://www.apic.org/Resource_/TinyMceFileManager/Practice_Guidance/HH-Surv-Def.pdf. Accessed 21 March 2018.
15. Barr DA, Semple L, Seaton RA. Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2011; 31:2611–9.
16. Averill RJ, Norbert Goldfield MD, Jack S, et al. All Patient Refined Diagnosis Related Groups (APR-DRGs). Methodology Overview. Wallingford, CT: 3M Health Information Systems; 2003.
17. Mull HJ, Chen Q, O’Brien WI, et al. Comparing 2 methods of assessing 30-day readmissions: what is the impact on hospital profiling in the Veterans Health Administration? Med Care 2013; 51:589–96.
18. Tice AD, Rehm SJ, Dalovisio JR, et al; IDSA. Practice guidelines for outpatient parenteral antimicrobial therapy: IDSA guidelines. Clin Infect Dis 2004; 38:1651–72.
19. Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoeconomic Outcomes Res 2015; 5:447–57.
20. Youngster I, Shemyo ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis 2014; 59:369–75.
21. Flynt LK, Kenney RM, Zervos MJ, Davis SL. The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther 2017; 6:225–31.
22. Lee S, Song KH, Jung SI, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteremia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect 2018; 24:152–158.
23. McDaniel JS, Roghmann MC, Perencevich EN, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis 2017; 65:100–6.
24. Lane MA, Marshall J, Beekmann SE, et al. Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians. Infect Control Hosp Epidemiol 2014; 35:839–44.
25. Cox JC, Sadiraj V, Schnier KE, Sweeney JE. Incentivizing cost-effective reductions in hospital readmission rates. J Econ Behav Organ 2016; 131:24–35.
26. Touzard Romo F, Resnick B, Perez-Cioe M, et al. Outpatient parenteral antibiotic therapy practices among adult infectious disease physicians. Infect Control Hosp Epidemiol 2014; 35:839–44.
27. Heintz BH, Halliwell J, Christensen CL. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center. Ann Pharmacother 2011; 45:1329–37.
28. Madaline T, Nori P, Mowrey W, et al. Bundle in the Bronx: impact of a transition-of-care outpatient parenteral antibiotic therapy bundle on all-cause 30-day hospital readmissions. Open Forum Infect Dis 2017; 4:sfo097.
29. Chitnis AS, Edwards JR, Ricks PM, et al. Outpatient parenteral antimicrobial therapy in hospital readmission rates. J Econ Behav Organ 2016; 98:38–42.
30. Heintz BH, Halliwell J, Christensen CL. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center. Ann Pharmacother 2011; 45:1329–37.
31. Smith PW, Rasmak PG. Infection prevention and control in the long-term-care facility. SHEA Long-Term-Care Committee and APIC Guidelines Committee. Am J Infect Control 1997; 25:488–512.
32. Richards CJ, Jr. Infection control in long-term care facilities. J Am Med Dir Assoc 2007; 8:S18–25.